Olema Pharmaceuticals Inc. (OLMA) is gearing up to present mature clinical data from its Phase 1b/2 study of palazestrant or OP-1250 in combination with ribociclib. The data will be featured at the European Society for Medical Oncology (ESMO) Congress, scheduled to take place in Berlin, Germany, from October 17 to 21, 2025.
Palazestrant is Olema's lead investigational therapy, a novel oral estrogen receptor (ER) antagonist and selective ER degrader, being developed for the treatment of ER-positive, HER2-negative advanced or metastatic breast cancer. The combination with ribociclib, a CDK4/6 inhibitor, is designed to address resistance mechanisms that often emerge during endocrine therapy, particularly in patients with ESR1 mutations.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.